Please login to the form below

Not currently logged in
Email:
Password:

Merck's Saphris cleared for new uses

Merck has won US Food and Drug Administration approval of new indications for its atypical antipsychotic Saphris

Merck has won US Food and Drug Administration (FDA) approval of new indications for its atypical antipsychotic Saphris (asenapine).

The sublingual tablets may now be marketed for the treatment of schizophrenia in adults, as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Saphris won its initial US approval in mid-August of last year for the acute treatment of schizophrenia in adults and as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.

Earlier this month, the drug, which Merck markets as Sycrest outside the US, won approval throughout the EU for treating moderate to severe manic episodes in adult patients with bipolar I disorder. However, European authorities declined to approve the drug as a treatment of schizophrenia.

Saphris was acquired in late-stage clinical development by Schering-Plough as part of the company's 2007 merger with Organon International. Merck and Schering-Plough merged last year.

Merck has not yet reported sales figures for the recently launched drug.

8th September 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...